|Tested species reactivity||Chemical|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG|
|Conjugate||Alexa Fluor® 488|
|Storage buffer||PBS, pH 7.2|
|Contains||5mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (IHC)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a synthetic nucleoside that is an analogue of thymidine. BrdU is commonly used in the detection of proliferating cells in living tissues. BrdU can be incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication. Antibodies specific for BrdU can then be used to detect the incorporated chemical, thus indicating cells that were actively replicating their DNA. Binding of the antibody requires denaturation of the DNA, usually by exposing the cells to acid or heat.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
FANCD2 influences replication fork processes and genome stability in response to clustered DSBs.
B35130 was used in flow cytometry to show that FANCD2 is needed for genome stability maintenance in response to high-linear energy transfer radiation
|Zhu J,Su F,Mukherjee S,Mori E,Hu B,Asaithamby A||Cell cycle (Georgetown, Tex.) (14:1809)||2015|
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
B35130 was used in flow cytometry to determine deubiquitinases required to assemble homologous recombination factors BRCA1 and RAD51
|Yu H,Pak H,Hammond-Martel I,Ghram M,Rodrigue A,Daou S,Barbour H,Corbeil L,Hébert J,Drobetsky E,Masson JY,Di Noia JM,Affar el B||Proceedings of the National Academy of Sciences of the United States of America (111:285)||2014|
Nuclear envelope protein Lem2 is required for mouse development and regulates MAP and AKT kinases.
B35130 was used in immunohistochemistry - frozen section to characterize mice harboring a disrupted allele for the Lem2 gene
|Tapia O,Fong LG,Huber MD,Young SG,Gerace L||PloS one (10:null)||2015|
RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression.
B35130 was used in immunocytochemistry to study the involvement of RASSF1A inactivation in carcinogenesis
|Ram RR,Mendiratta S,Bodemann BO,Torres MJ,Eskiocak U,White MA||Molecular and cellular biology (34:2350)||2014|
|Not Applicable||Not Cited||
Cell-cycle analyses using thymidine analogues in fission yeast.
B35130 was used in immunocytochemistry to evaluate the effectiveness of thymidine analogues for cell cycle studies in fission yeast
|Anda S,Boye E,Grallert B||PloS one (9:null)||2014|
|Not Applicable||Not Cited||
Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.
B35130 was used in flow cytometry to examine the combination treatment of prostate cancer cells with bortezomib and the C-terminal part of the p21(WAF1/CIP1) protein bound to the Elastin-like polypeptide carrier.
|Mikecin AM,Walker LR,Kuna M,Raucher D||Anti-cancer drugs (25:189)||2014|
Regulation of p27Kip1 by Sox2 maintains quiescence of inner pillar cells in the murine auditory sensory epithelium.
B35130 was used in immunohistochemistry to investigate the role of Sox2 in postmitotic cells.
|Liu Z,Walters BJ,Owen T,Brimble MA,Steigelman KA,Zhang L,Mellado Lagarde MM,Valentine MB,Yu Y,Cox BC,Zuo J||The Journal of neuroscience : the official journal of the Society for Neuroscience (32:10530)||2012|
The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS.
B35130 was used in immunohistochemistry to discuss the anatomical structures involved in the transport of intranasally administered drugs into the central nervous system.
|Scranton RA,Fletcher L,Sprague S,Jimenez DF,Digicaylioglu M||PloS one (6:null)||2011|